Market revenue in 2024 | USD 209.8 million |
Market revenue in 2030 | USD 330.2 million |
Growth rate | 7.9% (CAGR from 2025 to 2030) |
Largest segment | Implantable cardioverter defibrillators |
Fastest growing segment | Ventricular Assist Devices |
Historical data | 2018 - 2023 |
Base year | 2024 |
Forecast period | 2025 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Ventricular Assist Devices, Implantable Cardioverter Defibrillators, Pacemakers, Cardiac Resynchronization therapy, Counter Pulsation Devices |
Key market players worldwide | Medtronic PLC, Boston Scientific Corp, Abbott Laboratories, Jarvik Heart, ReliantHeart, Biotronik SE & Co., KG, Berlin Heart GmbH |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to congestive heart failure treatment devices market will help companies and investors design strategic landscapes.
Implantable cardioverter defibrillators was the largest segment with a revenue share of 34.37% in 2024. Horizon Databook has segmented the Japan congestive heart failure treatment devices market based on ventricular assist devices, implantable cardioverter defibrillators, pacemakers, cardiac resynchronization therapy, counter pulsation devices covering the revenue growth of each sub-segment from 2018 to 2030.
Japan holds a considerable share of the Asian CHF treatment devices market. Japan is witnessing a rapidly aging population and a combined shift toward the western diet and lifestyle is engendering the incidence of coronary diseases thereby leading to a greater demand for these devices.
With a huge healthcare expenditure, Japan’s healthcare system is witnessing a transition, expanding the service portfolio from preventive care to nursing care in disease management. The “21st-century type social security scheme” is expected to open more avenues for the tumor ablation market. Thus, the Japanese market is anticipated to account for around 39.9% of the market share of the overall Asia Pacific CHF treatment devices market in 2015.
Horizon Databook provides a detailed overview of country-level data and insights on the Japan congestive heart failure treatment devices market, including forecasts for subscribers. This country databook contains high-level insights into Japan congestive heart failure treatment devices market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account